



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,053	04/03/2002	Timothy James Jegla	18510-002030US	3563

20350 7590 12/27/2004

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER

CHANDRA, GYAN

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 12/27/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/914,053

Applicant(s)

JEGLA ET AL.

Examiner

Gyan Chandra

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 October 2004.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,2,6,7,13,23 and 24 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,2,13,23 and 24 is/are rejected.
- 7) ☐ Claim(s) 6 and 7 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 21 August 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 04/03/2002
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Election/Restrictions

Applicant's election with traverse of Group I, claims 1-13, 15, 23, and 24, in the reply filed on 10/18/2004 is acknowledged. The traversal is on the ground(s) that the claims of Groups I – XIV would not pose any undue burden on the Examiner. This is not found persuasive because the restriction is made under 371, and Groups 1-XIV lack unity of Invention. The Examiner has shown that the special technical features of Groups I, is a nucleic acid, the special technical feature of Group is detecting a nucleic acid, the special technical feature of Group III is a polypeptide, the special technical feature of Group IV is an antibody for the reason in the previous office action (see Paper mailed on 07/15/2004). Accordingly, Groups I-XIV are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept. Thus, unit of invention is lacking.

Applicant's election of polynucleotide sequence of SEQ ID NO: 5, is a restriction requirement (see, prior Office Action on 07/15/04). It is not a species election as noted in the Applicant's remarks. The species election was applicable for the polynucleotide sequences (primers) recited in claim 8, which has been canceled.

The requirement is still deemed proper and is therefore made FINAL.

Claims 3-5, 8-12, 14-22, and 25-56 are cancelled.

Claims 1,2,6, 7 and 13 are amended.

Claims 1-2, 6-7, 13, and 23-24 are examined on the merits to the extent that they read on the elected nucleic acid of SEQ ID NO: 6 that encodes the polypeptide of SEQ ID NO: 5.

Priority

The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application); the disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

Bib data sheet of the instant application claims priority of PCT/US00/04441 filed on 02/22/2000. Whereas, the specification claims priority of US 60/121,224, filed on 02/23/1999 and US 60/163,367, filed on 11/03/1999.

Claim Objections

Claims 1, 2, 6, 7, 13 and 23-24 are objected to as containing non-elected subject matter. Claim would be examined only to the extent so for it reads on nucleic acid sequence of SEQ ID NO: 6. It is suggested that Applicant amend claims 1,2,6,7 and 13 to delete the non-elected subject matter.

Claims 6 and 7 are objected as being directly or indirectly dependent from rejected claim(s).

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-2, 13, and 23-24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to a polynucleotide encoding polypeptide having greater than 70% identity with the polypeptide of amino acid SEQ ID NO: 5, and an expression vector comprising a polynucleotide having greater than 70% identity with the polypeptide encoded by the SEQ ID: 6. The claims do not require that the polypeptide possess any particular conserved structure, or any other disclosed distinguished feature. Thus the claims are drawn to a genus of nucleic acids that is defined solely by sequence identity or hybridization ability.

To provide undisclosed possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics for the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of

Art Unit: 1646

making the chemical product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

This is a written description rejection, rather than an enablement rejection under 35 U.S.C. 112, first paragraph. Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, & 1 "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001.

Vas-Cath Inc. V. Mahurka, 19 USPQ2d 1111, states that Applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention, for purposes of the Awritten description inquiry, is *whatever is now claimed* (see page 1117). The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (see *Vas-Cath* at page 1116).

A description of a genus may be achieved by means of a recitation of a representative number of species falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus. *Regents of the University of California v. Eli Lilly &*

Art Unit: 1646

Co., 119 F3d 1559, 1569, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997). In *Regents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the court held that a generic statement which defines a genus of nucleic acids by only their functional activity does not provide an adequate written description of the genus. The court indicated that, while applicants are not required to disclose every species encompassed by a genus, the description of the genus is achieved by the recitation of a representative number of species falling within the scope of the claimed genus. At section B (1), the court states an adequate written description of a DNA ... requires a precise definition, such as by structure, formula, chemical name, or physical properties, not a mere wish or plan for obtaining the claimed chemical invention.

As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen v. Baird*, 30 Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 148 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. Therefore, only the isolated polynucleotide encoding the polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 5, but not the breadth of the claims meet the written description provision of 35 U.S.C. § 112, first paragraph.

Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 1115).

Claims 1-2, 13, and 23-24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The first paragraph of 35 U.S.C. 112 states, "The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same...". The courts have interpreted this to mean that the specification must enable one skilled in the art to make and use the invention without undue experimentation. The courts have further interpreted undue experimentation as requiring "ingenuity beyond that to be expected of one of ordinary skill in the art" (Fields v. Conover, 170 USPQ 276 (CCPA 1971)) or requiring an extended period of experimentation in the absence of sufficient direction or guidance (In re Colianni, 195 USPQ 150 (CCPA 1977)). Additionally, the courts have determined that "... where a statement is, on its face, contrary to generally accepted scientific principles", a rejection for failure to teach how to make and/or use is proper (In re Marzocchi, 169 USPQ 367 (CCPA 1971)). Factors to be considered in determining whether a disclosure meets the enablement

Art Unit: 1646

requirement of 35 U.S.C. 112, first paragraph, have been described in In re Colianni, 195 USPQ 150, 153 (CCPA 1977) and have been clarified by the Board of Patent Appeals and Interferences in Ex parte Forman, 230 USPQ 546 (BPAI 1986). Among the factors are the nature of the invention, the state of the prior art, the predictability or lack thereof in the art, the amount of direction or guidance present, the presence or absence of working examples, the breadth of the claims, and the quantity of experimentation needed. The instant disclosure fails to meet the enablement requirement for the following reasons:

The Nature of Invention: The claimed invention is drawn to a polynucleotide encoding a polypeptide having the amino acid sequence greater than 70% identity to the S1-S2 region or polypeptide of SEQ ID NO: 5, an expression vector comprising the polynucleotide encoding a polypeptide having greater than 70% identity with the polypeptide of SEQ ID NO: 5, and that it forms a Slo potassium channel with an alpha subunit polypeptide.

The state of the prior art and the predictability or lack thereof in the art. The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinants to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. These regions can tolerate

only relatively conservative substitutions or no substitution (see Bowie et.al., 1990, Science 247: 1306-1310, page. 1306, column 2, paragraph2; Wells, 1990, Biochemistry 29:8509-8517)

The amount of direction or guidance present and the presence or absence of

working examples: Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary art to determine, without undue experimentation, the positions in the protein which are tolerant to change (e.g., by amino acid substations or deletions), and the nature and extent of changes that can be made in these positions. Although the specification outlines art-recognized procedures for producing and screening a protein having greater than 70% identity, and requires that a sequence homology of greater than 70% to the S1-S2 region of protein of SEQ ID NO: 5, it is merely an invitation to the artisan to use the invention as a starting point for further experimentation. Even if a protein with greater than 70% homology was identified in the specification, they may not be sufficient, as the ordinary artisan would immediately recognize that a functional protein must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy function of the protein. Therefore a large number of experimentation would be required to obtain a functional protein with greater than 70% identity with SEQ ID NO: 5. Furthermore, once a protein is obtained with greater than 70% identity with SEQ ID NO: 5, it would require to huge experimentation to evaluate its functionality.

The breadth of the claims and the quantity of experimentation needed: Due to the large quantity of experimentation necessary to generate the indefinite number of derivatives recited in the claims and screen same for activity, the lack of direction/guidance presented in the specification regarding which structural features are required in order to provide activity, the absence of working examples directed to same, the complex nature of invention, the state of prior art which establishes unpredictability of the effects of mutation on protein structure and function, and the breadth of the claims which fail to recite any structural or functional limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

Claim 24 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claim 24 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated or cultured cell comprising an expression vector, does not reasonably provide enablement for a host cell comprising an expression vector. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The Examiner has interpreted the claim as reading on isolated host cells, as well as host cells in the context of a multicellular, transgenic organism and host cells

Art Unit: 1646

intended for gene therapy. The specification of the instant application teaches that a protein encoded by gene of SEQ ID NO: 6 can be expressed in transgenic animals and any technique known in the art may be used to introduce the transgene into animals to produce the founder lines of transgenic animals (section, Cellular transfection and Gene therapy pages 49-54). However, there are no methods or working examples disclosed in the instant application whereby a multicellular animal with the incorporated BK4 gene of SEQ ID NO: 6 is demonstrated to express the BK4 peptide. There are also no methods or working examples in the specification indicating that a multicellular animal has BK4 "knocked out". The unpredictability of the art is *very high* with regards to making transgenic animals. For example, Wang et al. (Nuc. Acids Res. 27: 4609-4618, 1999; pg 4617) surveyed gene expression in transgenic animals and found in each experimental animal with a single "knock-in" gene, multiple changes in genes and protein products, often many of which were unrelated to the original gene. Likewise, Kaufman et al (Blood 94: 3178-3184, 1999) found transgene expression levels in their transfected animals varied from "full" (9 %) to "intermediate" to "none" due to factors such as "vector poisoning" and spontaneous structural rearrangements (pg 3180, col 1, 2nd full paragraph; pg 3182-3183). Additionally, for example, the specification discloses that two possible techniques used to introduce a BK4 transgene include non-viral delivery of nucleic acid (microinjection, biolistics, liposomes, virosomes, naked DNA) and DNA or RNA based viral delivery in mammals including patients. However, the literature teaches that the production of transgenic animals by microinjection of embryos suffers from a number of limitations, such as the extremely low frequency of integration

events and the random integration of the transgene into the genome which may disrupt or interfere with critical endogenous gene expression (Wigley et al. *Reprod Fert Dev* 6: 585-588, 1994). The inclusion of sequences that allow for homologous recombination between the transgenic vector and the host cell's genome does not overcome these problems, as homologous recombination events are even rarer than random events. Therefore, in view of the extremely low frequency of both targeted and non-targeted homologous recombination events in microinjected embryos, it would have required undue experimentation for the skilled artisan to have made any and all transgenic non-human animals according to the instant invention. Furthermore, regarding gene targeting in embryonic stem cells, the specification does not provide guidance for identifying and isolating embryonic stem cells or for identifying other embryonal cells which are capable of contributing to the germline of any animal. At the time of filing, Campbell et al. teaches that, "in species other than the mouse the isolation of ES cells has proved more difficult. There are reports of ES-like cell lines in a number of species... However, as yet there are not reports of any cell lines which contribute to the germ line in any species other than mouse" (Campbell et al. *Theriogenology* 47(1): 63-72, 1997; see pg 65, 2nd paragraph). Thus, based on the art recognized unpredictability of isolating and using embryonic stem cells or other embryonal cells from animals other than mice to produce transgenic animals, and in view of the lack of guidance provided by the specification for identifying and isolating embryonal cells which can contribute to the germ line of any non-human mammal other than the mouse, such as dogs or cows,

Art Unit: 1646

the skilled artisan would not have had a reasonable expectation of success in generating any and all non-human transgenic animals using ES cell technology.

The specification also discloses that "nucleotide constructs encoding such BK4 protein can be used to genetically engineer host cells to express such products in vivo" and that these products can be used in gene therapy approaches for the modulation of BK4 expression. However, the specification does not teach any methods or working examples that indicate a BK4 nucleic acid is introduced and expressed in a cell for therapeutic purposes. The disclosure in the specification is merely an invitation to the artisan to use the current invention as a starting point for further experimentation. For example, the specification does not teach what type of vector would introduce the BK4 nucleic acid into the cell or in what quantity and duration. Relevant literature teaches that since 1990, about 3500 patients have been treated via gene therapy and although some evidence of gene transfer has been seen, it has generally been inadequate for a meaningful clinical response (Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001; abstract). Additionally, the major challenge to gene therapy is to deliver DNA to the target tissues and to transport it to the cell nucleus to enable the required protein to be expressed (Phillips, A.; pg 1170, ¶ 1). Phillips also states that the problem with gene therapy is two-fold: 1) a system must be designed to deliver DNA to a specific target and to prevent degradation within the body, and 2) an expression system must be built into the DNA construct to allow the target cell to express the protein at therapeutic levels for the desired length of time (pg 1170, ¶ 1). Therefore, undue experimentation would be required of the skilled artisan to introduce and express a BK4 nucleic acid into the cell of

Art Unit: 1646

an organism. Additionally, gene therapy is unpredictable and complex wherein one skilled in the art may not necessarily be able to introduce and express a BK4 nucleic acid in the cell of an organism or be able to produce a BK4 protein in that cell.

Due to the large quantity of experimentation necessary to generate a transgenic animal expressing the BK4 protein and to introduce and express a BK4 nucleic acid in a cell of an organism for therapy, the lack of direction/guidance presented in the specification regarding how to introduce a BK4 nucleic acid in the cell of an organism to be able produce that BK4, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art which establishes the unpredictability of making transgenic animals and the unpredictability of transferring genes into an organism's cells, and the breadth of the claims which fail to recite any cell type limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope. (This rejection could be overcome by amending the claims to recite, for example, "An isolated host cell...").

Claim Rejections - 35 USC § 102

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-2, 13, and 23-24 are rejected under 35 U.S.C. 102(a) as being anticipated by Wallner et al. (Proc. Natl. Acad. Sci. USA 96: 4137-4142, 1999).

Wallner et al. teach coexpression of the human $\beta 2$ subunit with the pore-forming α subunit of human Slo (MaxiK channels) to induce fast activating current (see page 4138, left column, last paragraph). See also attached sequence alignment,

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gyan Chandra whose telephone number is (571) 272-2922. The examiner can normally be reached on 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gyan Chandra
AU 1646
20 December 2004


JANET ANDRES
PRIMARY EXAMINER